NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
Clinical Trials
18 trialsNCT02573896 2026-03-23
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT06450041 2026-03-23
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT07375563 2026-01-29
NB-NK-2026
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT07334301 2026-01-12
BEACON2
University of Birmingham
Phase 1/2 Recruiting
NCT07318831 2026-01-06
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05400603 2025-12-26
Aflac-NBL-2002
Emory University
Phase 1 Recruiting
NCT07261241 2025-12-03
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Not yet recruiting
NCT05080790 2025-08-17
DiTuSarc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT06485947 2025-07-08
DBPilot
Princess Maxima Center for Pediatric Oncology
Phase 1 Recruiting
NCT04211675 2025-05-13
STING
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT03332667 2025-04-16
MIBG With Dinutuximab +/- Vorinostat
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT06669013 2024-11-01
FollowTheDIN
N.N. Petrov National Medical Research Center of Oncology
Phase 3 Recruiting
NCT02308527 2024-05-14
BEACON
University of Birmingham
Phase 2 Active not recruiting
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT02641782 2022-11-04
NB2013-HR
University of Cologne
Phase 2 Terminated
NCT02743429 2021-10-04
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
University Medicine Greifswald
Phase 2 Unknown